Want to see TSE:KNE full AI Analyst Report?
Kane Biotech (KNE) AI Stock Analysis
Top Page
Kane Biotech
(TSXV:KNE)
The score is driven primarily by very weak financial performance (collapsing TTM revenue, deeply negative margins, negative equity, and sustained cash burn). Technicals add further pressure with the stock trading below major moving averages and only neutral momentum signals. Valuation provides little support due to negative earnings and no dividend yield.
Kane Biotech (KNE) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 6.15M
- Dividend Yield
- ―
- Average Volume (3M)
- 119.84K
- Price to Earnings (P/E)
- -2.1
- Beta (1Y)
- 0.50
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Canada
- Employees
- 32
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Kane Biotech Business Overview & Revenue Model
Company Description
Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbial b...
How the Company Makes Money
Kane Biotech makes money primarily by commercializing biofilm-disruption technologies and related products, and by monetizing its intellectual property through partnered products. Key revenue streams include: (1) Product sales in animal health and wo...
Kane Biotech Earnings Call Summary
The earnings call highlighted significant revenue growth driven by new product sales and service revenue streams. Strategic partnerships, regulatory approvals, and expansion into new markets were noted as positive developments. However, increased operating expenses and a decrease in cash reserves were challenges mentioned. Overall, the positive developments notably outweigh the drawbacks.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During Kane Biotech's Q3 2024 earnings call, the guidance highlighted several key achievements and future expectations. The company recorded its first commercial sales of revyve Antimicrobial Wound Gel, contributing to product sales of $598,000 for the quarter, compared to just $4,000 in Q3 2023. Total revenue reached $1,283,000, significantly up from $27,000 in the previous year, with a gross profit of $559,000. Operating expenses increased by 18% to $1,170,000. Despite these expenses, the net loss from continuing operations decreased by 45% to $679,000. Kane Biotech is anticipating further growth, with plans for additional distribution agreements, regulatory approvals, and the launch of new products, including DispersinB Wound Gel trials and potential enhancements to their Lumixa product. Additionally, a $3 million private placement was announced to support these initiatives.
Kane Biotech Financial Statement Overview
Summary
Financials are very weak: TTM revenue is extremely low (38.7k) and down sharply (-33.9%), margins are deeply negative (gross margin -503%, net margin -6,980%), equity is negative (TTM -994k), and cash burn remains heavy (TTM operating cash flow -2.50M; free cash flow -2.42M). Modest debt reduction and slightly improved burn versus 2025 are minor positives but do not offset solvency and funding risk.
Income Statement
9Very NegativeBalance Sheet
18Very NegativeCash Flow
11Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.72K | 427.87K | 2.08M | 148.98K | 156.73K | 1.61M |
| Gross Profit | -194.80K | -163.38K | 872.10K | 109.47K | 1.41M | 568.44K |
| EBITDA | -3.07M | -2.95M | -3.71M | -3.11M | -2.95M | -4.25M |
| Net Income | -2.70M | -2.72M | -3.02M | -5.03M | -3.89M | -4.60M |
Balance Sheet | ||||||
| Total Assets | 2.23M | 2.73M | 2.49M | 5.68M | 5.62M | 6.13M |
| Cash, Cash Equivalents and Short-Term Investments | 854.73K | 901.70K | 358.81K | 749.25K | 1.10M | 1.15M |
| Total Debt | 1.96M | 2.30M | 2.29M | 9.26M | 6.86M | 4.71M |
| Total Liabilities | 3.22M | 3.48M | 4.12M | 14.09M | 9.76M | 7.70M |
| Stockholders Equity | -993.86K | -746.54K | -1.63M | -10.56M | -6.52M | -3.89M |
Cash Flow | ||||||
| Free Cash Flow | -2.42M | -3.26M | -4.14M | -3.23M | -3.13M | -2.64M |
| Operating Cash Flow | -2.50M | -3.26M | -4.11M | -3.22M | -3.04M | -2.29M |
| Investing Cash Flow | -12.63K | -53.13K | 10.27M | -116.14K | -107.55K | -373.55K |
| Financing Cash Flow | 1.75M | 3.85M | -7.69M | 2.98M | 3.10M | 2.81M |
Kane Biotech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 48.63 is Neutral, neither overbought nor oversold. The STOCH value of 116.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KNE.
Kane Biotech Peers Comparison
Overall Rating
TSE:MOOD42Neutral- TSE:KNE41Neutral
TSE:BIOV28.5Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:MOOD | 42Neutral | CAD 680.99K | -0.57 | -85.01% | ― | 73.76% | -108.30% |
| TSE:KNE | 41Neutral | CAD 6.15M | -2.05 | 273.53% | ― | ― | ― |
| TSE:BIOV | 29Underperform | CAD 2.04M | -0.91 | 69.89% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:KNE | Kane Biotech | 0.03 | 0.00 | 0.00% | |
| TSE:QPT | Quest Pharmatech | 0.02 | -0.02 | -50.00% | |
| TSE:BIOV | Biovaxys Technology Corp | 0.07 | -0.19 | -73.08% | |
| TSE:MOOD | Doseology Sciences, Inc. | 0.09 | -0.26 | -75.71% |
Kane Biotech Corporate Events
Kane Biotech Hires ITG to Boost Liquidity in TSXV-Listed Shares
PositiveKane Biotech has engaged Toronto-based Independent Trading Group as a market maker for its common shares, pending TSX Venture Exchange approval, in a bid to support an orderly market and enhance share liquidity across the TSXV and other trading venue...
Kane Biotech Taps Stevens Company to Broaden Canadian Wound-Care Reach
PositiveKane Biotech has signed a non-exclusive distribution agreement with The Stevens Company to expand Canadian access to its Health Canada-licensed revyve antimicrobial wound gel and spray products. Under the deal, Stevens will purchase and resell revyve...
Kane Biotech to Spotlight revyve Biofilm Wound-Care Line at Wounds Canada Conference
PositiveKane Biotech will showcase its U.S. FDA-cleared and Health Canada-approved revyve antimicrobial wound-care products at the Wounds Canada National Hybrid Conference in Niagara Falls from October 22 to 24, 2026. The company plans to engage clinicians,...
Kane Biotech Refreshes Brand and Website to Support Wound-Care Growth
PositiveKane Biotech Inc., a Winnipeg-based biotechnology company, specializes in biofilm-disrupting technologies and advanced wound-care products designed to improve healing outcomes and combat antibiotic resistance. Its revyve line of antimicrobial wound g...
Kane Biotech Secures $250,000 Insider Loan to Support Working Capital
PositiveKane Biotech has secured a $250,000 unsecured, non-interest-bearing insider loan from board chair and control person Philip Renaud to bolster its working capital. The funds will be used for general corporate purposes and are repayable on demand, with...
Kane Biotech to Highlight revyve Clinical Data and Expand Distribution at SAWC Fall 2026
PositiveKane Biotech will present new clinical and health-economic data on its revyve antimicrobial wound-care products at the SAWC Fall 2026 conference in Las Vegas. The company will highlight findings on chronic wound healing trajectories, tissue oxygenati...
Kane Biotech Schedules Webcast to Detail Wound-Care Commercial Strategy
PositiveKane Biotech will host a virtual Commercial Update webcast on September 16, 2026, to brief shareholders, prospective investors and other stakeholders on its progress in building a clinically credible and commercially disciplined wound-care business....
Kane Biotech Expands Canadian Reach for revyve Wound Care via Ontario Medical Supply Deal
PositiveKane Biotech has signed a non-exclusive distribution agreement with Ontario Medical Supply Inc. to expand the reach of its revyve advanced wound care products across Canada. Under the deal, OMS will purchase, market and support Kane’s FDA-clear...
Kane Biotech Widens Q2 Loss as It Accelerates Shift to Human Wound Care
NegativeKane Biotech reported second-quarter 2026 revenue of $8,143, down from $27,997 a year earlier, reflecting its early-stage commercialization of the revyve wound care line following the exit from legacy businesses. Gross profit improved to $1,444 from...
Kane Biotech’s revyve Wound Care Technology Draws Military Research Interest
PositiveKane Biotech announced that research on its revyve Antimicrobial Wound Gel Spray was presented at the Military Health System Research Symposium in Florida, highlighting its broad-spectrum, cavity-filling capabilities for prolonged field care and comp...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 09, 2026